Immunotherapy with dendritic cells for gynecological neoplasias: a new therapeutic approach?

The immune system consists of a complex collection of mediators and cells that act in a coordinated way to eliminate neoplastic cells. One of immunotherapy's promises is the development of cellular vaccines, or more specifically, vaccines with dendritic cells. However, we still have a lot left to study and learn, since we already know that patients with tumors of the same histological grade can have completely different behaviors when given the same immunological stimulus. We believe that antitumor immunotherapy will lead to a personalized vaccine, since the scheme of treatment, the stimuli and the dosages need to be tailored to each patient.

Immunotherapy; Dendritic cells; Neoplasia

[1] Barling B.: “Multiple myelomatosis with remission following erysipelas”. Proc. R. Soc. Med., 1949, 42, 175.

[2] Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V.: “Coordinated regulation of myeloid cells by tumors”. Nat. Rev. Immunol., 2012, 22, 253.

[3] Nagaraj S., Gabrilovich D.I.: “Tumor escape mechanism governed by myeloid-derived suppressor cells”. Cancer Res., 2008, 68, 2561.

[4] Kusmartsev S., Gabrilovich D.I.: “Role of immature myeloid cells in mechanisms of immune evasion in cancer”. Cancer Imm., Immunother., 2006, 55, 237.

[5] Terme M., Chaput N., Combadiere B., Averil M., Ohteki T., Zitvogel L.: “Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells”. J. Immunol., 2008, 180, 4679.

[6] Antony P.A., Piccirillo C.A., Akpinarli A., Finkelstein S.E., Speiss P.J., Surman D.R. et al.: “CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells”. J. Immunol., 2005, 174, 2591.

[7] Misson D.R., Abdalla D.R., Borges A.M., Shimba D.S., Adad S.J., Michelin M.A. et al.: “Cytokine serum levels in patients with cervical intraepithelial neoplasia grade II-III treated with intralesional interferon-2b”. Tumori, 2011, 97, 578.

[8] Mardegan M.C., Ramos M.C., Adad S.J., Michelin M.A., Shimba D., Murta E.F.: “Immunological evaluation of vaginal secretion in patients with high-grade cervical intraepithelial neoplasia treated with intralesional interferon alpha-2b”. Eur. J. Gynaecol. Oncol., 2011, 32, 297.

[9] Ramos M.C., Mardegan M.C., Peghini B.C., Adad S.J., Michelin M.A., Murta E.F.: “Expression of cytokines in cervical stroma in patients with high-grade cervical intraepithelial neoplasia after treatment with intralesional interferon alpha-2b”. Eur. J. Gynaecol. Oncol., 2010, 31, 522.

[10] Steinman R.M., Cohn Z.A.: “Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution”. J. Exp. Med., 1973, 137, 1142.

[11] Banchereau J., Steinman, R.: “Dendritic cells and the control of immunity”. Nature, 1998, 19, 245.

[12] Fong L., Engleman E.G.: “Dendritic cells in cancer immunotherapy”. Ann. Rev. Immunol., 2000, 18, 245.

[13] Toebak M.J., Gibbs S., Bruynzeel D.P., Scheper R.J., Rustemeyer T.: “Dendritic cells: biology of the skin”. Contact Dermatitis, 2009, 60, 2.

[14] Kaisho T., Akira S.: “Toll-like receptors as adjuvant receptors”. Biochim Biophys Acta, 2002, 1589, 1.

[15] Vegh Z., Mazumder A.: “Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response”. Cancer Immunol. Immunother., 2003, 52, 67.

[16] Rodrigues C.M., Matias B.F., Murta E.F., Michelin M.A.: “The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells”. Clin. Med. Insights Oncol., 2011, 5, 107.